Prevention of Bladder Cancer with Broccoli Sprouts

用西兰花芽预防膀胱癌

基本信息

项目摘要

DESCRIPTION (provided by applicant): This project focuses on the cancer preventive activity of broccoli sprout extracts in the bladder. The hypothesis to be tested is that broccoli sprout extracts are able to suppress tumorigenesis in the bladder by inducing carcinogen-detoxifying enzymes, inducing apoptosis, and inhibiting cell proliferation, all of which contribute, perhaps synergistically, to the prevention of carcinogenesis. Molecular markers relevant to these biological events, as well as inhibition of tumorigenesis will be studied. Broccoli sprouts are the richest plant source of sulforaphane, which is known to possess the above-described chemopreventive mechanisms. Both sulforaphane and broccoli sprout extracts have been shown to inhibit tumorigenesis in animal models (non-bladder tissues). Particularly, ingested sulforaphane in humans is disposed rapidly and concentrated in urine, making bladder epithelial cells probably the most exposed cells to sulforaphane in the body. The overwhelming majority of bladder cancers originate from the epithelial cells. Aim 1 is to determine the effect of broccoli sprout extracts on the expression of critical Phase 2 detoxification enzymes in cultured human bladder epithelial cells. Glutathione transferase and UDP-glucuronosyl-transferase, whose deficiencies have been linked to bladder carcinogenesis, will be examined using both enzyme activity analysis and Western blot analysis. Aim 2 is to determine the effect of broccoli sprout extracts on apoptosis and cell cycle regulation in cultured human bladder epithelial cells. The biomarkers include nuclear DNA fragmentation, activation of selected caspases, cell cycle change and related cell cycle regulators, using both flow cytometry and Western blot analysis. Aim 3 is to determine the in vivo cancer chemopreventive activity of broccoli sprout extracts in the rat bladder. Aim 3a is designed to determine the effect of orally administered broccoli sprout extracts on Phase 2 enzymes, apoptosis, and cell proliferation in bladder epithelia. Biomarkers, including the two Phase 2 enzymes listed above, plus the TUNEL and PCNA assays, will be evaluated immunohistochemically. Aim 3b is to determine the effect of orally administered broccoli sprout extracts on N-butyl-N-(4-hydroxybutyl) nitrosamine-induced bladder tumorigenesis. Tumor incidence, tumor multiplicity, and the nature of each tumor will be determined.
描述(由申请人提供):该项目着重于膀胱中西兰花发芽提取物的癌症预防活性。要检验的假设是,西兰花发芽提取物能够通过诱导致癌氧化酶,诱导细胞凋亡和抑制细胞增殖来抑制膀胱中的肿瘤发生,从而抑制细胞增殖,所有这些酶,也许会导致促成预防性的致癌作用。将研究与这些生物学事件有关的分子标记物以及抑制肿瘤发生。西兰花新芽是磺胺硫烷的最丰富植物来源,已知具有上述化学预防机制。硫烷和西兰花发芽提取物均已证明可以抑制动物模型(非叶片组织)中的肿瘤发生。特别是,人类摄入的磺胺素迅速处置并浓缩在尿液中,使膀胱上皮细胞可能是体内硫磷酸硫烷最暴露的细胞。绝大多数膀胱癌源自上皮细胞。目的1是确定西兰花发芽提取物对培养的人膀胱上皮细胞中临界2期解毒酶表达的影响。谷胱甘肽转移酶和UDP-葡萄糖基转移酶的缺陷将与膀胱癌变有关,将使用酶活性分析和蛋白质印迹分析进行检查。目的2是确定西兰花发芽提取物对培养的人膀胱上皮细胞中细胞凋亡和细胞周期调节的影响。生物标志物包括核DNA碎片,所选胱天蛋白酶的激活,细胞周期变化和相关的细胞周期调节剂,都使用流式细胞仪和蛋白质印迹分析。目标3是确定大鼠膀胱中西兰花发芽提取物的体内癌症化学预防活性。 AIM 3A旨在确定口服的西兰花发芽提取物对膀胱上皮中2阶段酶,凋亡和细胞增殖的影响。生物标志物,包括上面列出的两种2期2酶,以及TUNEL和PCNA分析,将通过免疫组织化学评估。 AIM 3B是确定口服的西兰花发芽提取物对N-丁基N-(4-羟基丁基)硝基胺诱导的膀胱肿瘤发生的影响。将确定肿瘤的发病率,肿瘤多样性和每个肿瘤的性质。

项目成果

期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Atherosclerotic neovasculature MR imaging with mixed manganese-gadolinium nanocolloids in hyperlipidemic rabbits.
使用混合锰钆纳米胶体对高脂血症兔进行动脉粥样硬化新生血管 MR 成像。
Molecular imaging with computed tomography.
计算机断层扫描分子成像。
alphaVbeta3-targeted copper nanoparticles incorporating an Sn 2 lipase-labile fumagillin prodrug for photoacoustic neovascular imaging and treatment.
  • DOI:
    10.7150/thno.10014
  • 发表时间:
    2015
  • 期刊:
  • 影响因子:
    12.4
  • 作者:
    Zhang R;Pan D;Cai X;Yang X;Senpan A;Allen JS;Lanza GM;Wang LV
  • 通讯作者:
    Wang LV
Near infrared imaging of EGFR of oral squamous cell carcinoma in mice administered arsenic trioxide.
给予三氧化二砷的小鼠口腔鳞状细胞癌 EGFR 的近红外成像
  • DOI:
    10.1371/journal.pone.0046255
  • 发表时间:
    2012
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Zhang L;Wang K;Zhao F;Hu W;Chen J;Lanza GM;Shen B;Zhang B
  • 通讯作者:
    Zhang B
Synergy between surface and core entrapped metals in a mixed manganese-gadolinium nanocolloid affords safer MR imaging of sparse biomarkers.
混合锰钆纳米胶体中表面和核心包埋金属之间的协同作用可为稀疏生物标志物提供更安全的 MR 成像。
  • DOI:
    10.1016/j.nano.2014.12.009
  • 发表时间:
    2015-04
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Wang K;Pan D;Schmieder AH;Senpan A;Hourcade DE;Pham CT;Mitchell LM;Caruthers SD;Cui G;Wickline SA;Shen B;Lanza GM
  • 通讯作者:
    Lanza GM
共 7 条
  • 1
  • 2
前往

YUESHENG ZHANG的其他基金

Restore the Tumor-Suppressive Activities of p53 Mutants
恢复 p53 突变体的肿瘤抑制活性
  • 批准号:
    10716397
    10716397
  • 财政年份:
    2023
  • 资助金额:
    $ 23.42万
    $ 23.42万
  • 项目类别:
Combating Cetuximab Resistance in Colorectal Cancer
对抗结直肠癌中的西妥昔单抗耐药性
  • 批准号:
    10600411
    10600411
  • 财政年份:
    2022
  • 资助金额:
    $ 23.42万
    $ 23.42万
  • 项目类别:
Overcoming Drug Resistance in HER2-positive Breast Cancer
克服 HER2 阳性乳腺癌的耐药性
  • 批准号:
    10639498
    10639498
  • 财政年份:
    2020
  • 资助金额:
    $ 23.42万
    $ 23.42万
  • 项目类别:
Overcoming Drug Resistance in HER2-positive Breast Cancer
克服 HER2 阳性乳腺癌的耐药性
  • 批准号:
    10663396
    10663396
  • 财政年份:
    2020
  • 资助金额:
    $ 23.42万
    $ 23.42万
  • 项目类别:
Overcoming Drug Resistance in HER2-positive Breast Cancer
克服 HER2 阳性乳腺癌的耐药性
  • 批准号:
    10207554
    10207554
  • 财政年份:
    2020
  • 资助金额:
    $ 23.42万
    $ 23.42万
  • 项目类别:
Combating Cetuximab Resistance in Colorectal Cancer
对抗结直肠癌中的西妥昔单抗耐药性
  • 批准号:
    9287314
    9287314
  • 财政年份:
    2017
  • 资助金额:
    $ 23.42万
    $ 23.42万
  • 项目类别:
Combating Cetuximab Resistance in Colorectal Cancer
对抗结直肠癌中的西妥昔单抗耐药性
  • 批准号:
    9891024
    9891024
  • 财政年份:
    2017
  • 资助金额:
    $ 23.42万
    $ 23.42万
  • 项目类别:
Combating Cetuximab Resistance in Colorectal Cancer
对抗结直肠癌中的西妥昔单抗耐药性
  • 批准号:
    10115631
    10115631
  • 财政年份:
    2017
  • 资助金额:
    $ 23.42万
    $ 23.42万
  • 项目类别:
Combating Cetuximab Resistance in Colorectal Cancer
对抗结直肠癌中的西妥昔单抗耐药性
  • 批准号:
    9453661
    9453661
  • 财政年份:
    2017
  • 资助金额:
    $ 23.42万
    $ 23.42万
  • 项目类别:
Gender Disparity in Bladder Cancer and Chemopreventive Intervention
膀胱癌的性别差异和化学预防干预
  • 批准号:
    8605175
    8605175
  • 财政年份:
    2013
  • 资助金额:
    $ 23.42万
    $ 23.42万
  • 项目类别:

相似国自然基金

胸腺肽α-1介导凋亡小体RNA改善DC功能增强TNBC化疗后抗肿瘤免疫应答的机制研究
  • 批准号:
    82303959
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
抗凋亡的畸胎瘤发生坏死并释放APOE脂质颗粒以减弱T细胞抗肿瘤免疫
  • 批准号:
    82303354
  • 批准年份:
    2023
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目
CpG/cGAMP原位疫苗诱导的凋亡小体的抗肿瘤机制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    52 万元
  • 项目类别:
    面上项目
主动靶向纳米粒子TRAIL-Cur-NPs通过GSDMB介导的凋亡-焦亡转换增加结直肠癌放疗后淋巴细胞浸润增强抗肿瘤效应机制研究
  • 批准号:
    82260490
  • 批准年份:
    2022
  • 资助金额:
    33.00 万元
  • 项目类别:
    地区科学基金项目
激酶模拟肽组装体的细胞坏死凋亡激活及抗肿瘤研究
  • 批准号:
    52273130
  • 批准年份:
    2022
  • 资助金额:
    55.00 万元
  • 项目类别:
    面上项目

相似海外基金

Novel Substrate Competitive Bcr-Abl Inhibitor Active Against Gleevec-Resistant CM
新型底物竞争性 Bcr-Abl 抑制剂对格列卫耐药 CM 具有活性
  • 批准号:
    7046281
    7046281
  • 财政年份:
    2006
  • 资助金额:
    $ 23.42万
    $ 23.42万
  • 项目类别:
MECHANISMS BY WHICH IFN-GAMMA SEPARATES GVHD AND GVL
IFN-γ 分离 GVHD 和 GVL 的机制
  • 批准号:
    7158088
    7158088
  • 财政年份:
    2006
  • 资助金额:
    $ 23.42万
    $ 23.42万
  • 项目类别:
Targeted Therapy of Lyn in Myelodysplastic Syndrome
Lyn 治疗骨髓增生异常综合征的靶向治疗
  • 批准号:
    7034786
    7034786
  • 财政年份:
    2006
  • 资助金额:
    $ 23.42万
    $ 23.42万
  • 项目类别:
Analysis of Patient Tumor Responses to Apo2L/TRAIL
患者肿瘤对 Apo2L/TRAIL 的反应分析
  • 批准号:
    7034793
    7034793
  • 财政年份:
    2006
  • 资助金额:
    $ 23.42万
    $ 23.42万
  • 项目类别:
Efficacy and toxicity of TRAIL against gliomas
TRAIL对抗胶质瘤的功效和毒性
  • 批准号:
    7033212
    7033212
  • 财政年份:
    2006
  • 资助金额:
    $ 23.42万
    $ 23.42万
  • 项目类别: